DOCSLIB.ORG

And Long-Acting Loop Diuretics in Outpatients with Chronic Heart Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
And Long-Acting Loop Diuretics in Outpatients with Chronic Heart Failure Journal of Cardiology (2012) 59, 352—358 View metadata, citation and similar papers at core.ac.uk brought to you by CORE Available online at www.sciencedirect.com provided by Elsevier - Publisher Connector j ournal homepage: www.elsevier.com/locate/jjcc Original Article Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF) Masaaki Miyata (MD, FJCC), Takeshi Sasaki (MD), Yoshiyuki Ikeda (MD), Takuro Shinsato (MD), Takuro Kubozono (MD), Yuko Furusho (MD), Atsushi Kusumoto (MD), Shuichi Hamasaki (MD, FJCC), ∗ Chuwa Tei (MD, FJCC) , COLD-CHF Investigators Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medicine, Kagoshima University, Kagoshima, Japan Received 23 September 2011; received in revised form 7 December 2011; accepted 28 December 2011 Available online 24 February 2012 KEYWORDS Summary Background: Loop diuretics have two different classes with different duration of activity: short- Chronic heart failure; Diuretic; acting such as furosemide (duration of activity, 6 h) and long-acting such as azosemide (duration of activity, 10—12 h). We conducted a multicenter, randomized, controlled trial in order to Brain natriuretic peptide; compare the therapeutic effects of azosemide, a long-acting loop diuretic, and furosemide, a short-acting one, on neurohumoral factors and cardiac function in outpatients with chronic Atrial natriuretic peptide heart failure (CHF). Methods: We enrolled 98 patients with CHF who were receiving furosemide and an angiotensin- converting enzyme inhibitor, and they were randomly divided into furosemide (n = 49) and azosemide (n = 49) groups. The furosemide group continued furosemide at the same dosage, and the azosemide group switched from furosemide to azosemide. At baseline and after 3 months, we measured body weight, and levels of brain natriuretic peptide (BNP), atrial natri- uretic peptide (ANP), norepinephrine, active renin, creatinine, blood urea nitrogen, sodium, potassium, and hematocrit. Chest X-ray and echocardiography were also performed. Results: Body weight and plasma levels of BNP and ANP significantly decreased after 3 months in the azosemide group compared to the furosemide group. There were no significant differ- ences in changes of levels of creatinine, blood urea nitrogen, sodium, potassium, hematocrit, norepinephrine, and active renin after 3 months between the furosemide and azosemide groups. ∗ Corresponding author at: Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan. Tel.: +81 99 275 5316; fax: +81 99 275 5322. E-mail address: [email protected] (C. Tei). 0914-5087/$ — see front matter © 2012 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.jjcc.2011.12.007 Short- and long-acting diuretics in CHF 353 Echocardiography and chest X-ray did not demonstrate significant differences between the two groups. Conclusions: Long-acting azosemide is suggested to be useful for the improvement of neurohu- moral factors compared with short-acting furosemide in patients with CHF. © 2012 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. Introduction Study design Heart failure is a major and growing public health prob- This randomized multicenter clinical trial was conducted at lem, and the number of heart failure deaths has increased 16 hospitals in Japan from October, 2005 to January, 2008. steadily despite advances in treatment [1]. Diuretics have The patients were randomly divided into furosemide and been shown to improve cardiac function, symptoms, and azosemide groups by an envelope method. The furosemide exercise tolerance in patients with chronic heart failure group was assigned to continue receiving furosemide, and (CHF) [2—4]. Loop diuretics with strong diuretic effects are the azosemide group was assigned to switch from furosemide essential for the treatment of pulmonary congestion and to azosemide. Regarding the doses of both drugs, 20 and symptoms in heart failure patients [1]. The loop diuretics 40 mg furosemide was equivalent to approximately 30 and are categorized into short- and long-acting groups based on 60 mg azosemide, respectively, based on the results of a clin- their duration of action. Furosemide with rapid action is a ical pharmacology study [5]. Examinations were conducted potent diuretic representing the short-acting group, while 3 months after registration, and all clinical parameters were azosemide with a mild and long-lasting effect is representa- examined before and 3 months after assignment. Readers of tive of the long-acting group [5]. chest X-ray and echocardiography were blinded to the inves- Despite their hypotensive effects, short-acting calcium tigation in the treatment allocation, although the grouping channel blockers were reported to increase mortality in was open to physicians and patients. patients with cardiovascular disease, while long-acting cal- Concomitant ACE inhibitors already being used at enroll- cium channel blockers were not associated with increased ment were continued as prescribed. Other drugs were mortality in hypertensive patients [6,7]. This hypothesis also allowed to continue without making further changes can also be applied theoretically to diuretics with differ- after registration. Cases requiring any changes in medica- ent durations of action in patients with CHF. Azosemide, tion, including other heart failure drugs, were defined as a long-acting loop diuretic, was associated with a better dropouts. outcome in Dahl rat heart-failure models compared with The study design complied with the Declaration of short-acting furosemide, partly through attenuation of the Helsinki and was unanimously approved by the Ethics Com- reflex increase in cardiac sympathetic neuronal activity mittee of Kagoshima University. Written informed consent caused by the development of heart failure [8]. Further- was obtained before enrolment from all of the patients who more, the comparative effects of long-acting azosemide and participated in the present study. short-acting furosemide on neurohumoral factors, and the usefulness of azosemide for improving quality of life were Physical examination and chest X-ray shown in a clinical study [9,10]. However, these studies were only performed in a small number of patients in a single hos- pital, and thus the usefulness of long-acting diuretics has not The NYHA functional class, body weight, systolic blood yet been validated. Therefore, we conducted a multicenter pressure (SBP), diastolic blood pressure (DBP), and cardio- randomized controlled trial, and compared the effects of thoracic ratio (CTR) on chest radiography were determined azosemide on neurohumoral factors and cardiac function to before and 3 months after commencing the study. those of furosemide in outpatients with CHF of New York Heart Association (NYHA) class I—III. Laboratory examinations Methods A fasting blood sample was taken in the morning. The plasma Patients levels of BNP, atrial natriuretic peptide (ANP), norepineph- rine (NE), and renin activity, the serum levels of creatinine, blood urea nitrogen, sodium, potassium, and chloride, and We enrolled 98 consecutive CHF outpatients with NYHA class hematocrit were measured before and 3 months after assign- I—III whose brain natriuretic peptide (BNP) level was greater ment. than 20 pg/ml, who had been receiving an angiotensin- converting enzyme (ACE) inhibitor and furosemide for at least 1 month and were in a stable condition. They were Echocardiography not administered any angiotensin II type 1 receptor blocker (ARB). The diagnosis of heart failure was defined by symp- Cardiac function was evaluated by echocardiography toms, clinical signs, and BNP levels more than 100 pg/ml before and 3 months after the start of the clinical trial. before medication [11]. Standard two-dimensional and Doppler echocardiographic 354 M. Miyata et al. a Tei index Mitral = (ICT + IRT) / ET (Tricuspid ) ICT ET inflow IRT = (a –b) / b Aortic (Pulmonary ) ICT: isovo lumic contraction time ejection flo w IRT: isovolumic relaxation time bbc ET : ejection time ECG c d IRT Figure 1 Scheme and principle of measurement of Tei index. examinations were performed in all subjects using 1- to Figure 2 Changes in body weight (A) and cardiothoracic 5-MHz phased array transducers and commercially available ratio (CTR) on chest X-ray (B) after 3 months. White bars are scanners [12]. Left ventricular systolic dimension (LVDs) and furosemide group; black bars are azosemide group. diastolic dimension (LVDd), and left atrial dimension (LAD) were determined. Left ventricular ejection fraction (LVEF) Results was obtained by modified biplane Simpson’s method from apical 2- and 4-chamber views. LV mass was calculated by the American Society of Echocardiography-recommended Patient characteristics × { formula [13]: LV mass (g) = 0.8 1.04[(LVDd + posterior wall thickness + interventricular septum Ninety-eight patients were enrolled and randomly divided 3 − 3 } thickness) (LVDd) ] + 0.6 g. LV mass was divided by into furosemide and azosemide groups. One patient in the body surface area to obtain LV mass index (LVMI). azosemide group was excluded from the trial, because she Doppler time intervals were measured from the left ven- complained of frequent urination and refused the continu- tricular (LV) inflow and outflow velocities, and Tei index
Load more

Recommended publications
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • The Effect of Diuretics on Patients with Heart Failure: a Network Meta- Analysis: Diuretics Effect on Heart Failure Patients
    J Pharm Pharm Sci (www.cspsCanada.org) 22, 270 - 280, 2019 The Effect of Diuretics on Patients with Heart Failure: A Network Meta- Analysis: Diuretics Effect on Heart Failure Patients Xingsheng Zhao1, MD; Yu Ren2, MD; Hui Li1, MM; Xi Liu 1, MD 1Cardiology Department and 2Clinical Medical Research Center, Inner Mongolia People’s Hospital, Hohhot, Inner Mongolia Autonomous Region, China. Received, April 10, 2019; Revised, May 6, 2019; Accepted, June 12 2019; Published, June 13, 2019. ABSTRACT - Purpose: We aimed to comprehensively evaluate the curative effect of torasemide, tolvaptan, furosemide and azosemide on patients with heart failure. Methods: Relevant studies were retrieved by searching the electronic databases until May 2018. Quality assessment and data extraction of selected studies were evaluated by two reviewers. Heterogeneity across studies was assessed utilizing the I2 statistic and Q- test, and appropriate effect model was selected to calculate the pooled effect size. Network meta-analysis was conducted and the convergence degree of model was evaluated. Results: A total of 12 studies were enrolled in this study. Significant heterogeneity was not identified across the studies. Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison. In addition, network meta-analysis results suggested there were no significant differences in adverse effects, mortality, BNP and LVEF among these groups. However, the relatively low mortality and small improvement of BNP and LVEF were found in HF patients treated with torasemide.
    [Show full text]
  • Azosemide Is More Potent Than Bumetanide and Various Other Loop
    www.nature.com/scientificreports OPEN Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium- Received: 21 November 2017 Accepted: 14 June 2018 potassium-chloride-cotransporter Published: xx xx xxxx human variants hNKCC1A and hNKCC1B Philip Hampel 1,2, Kerstin Römermann1, Nanna MacAulay 3 & Wolfgang Löscher1,2 The Na+–K+–2Cl− cotransporter NKCC1 plays a role in neuronal Cl− homeostasis secretion and represents a target for brain pathologies with altered NKCC1 function. Two main variants of NKCC1 have been identifed: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B) that is particularly enriched in the brain. The loop diuretic bumetanide is often used to inhibit NKCC1 in brain disorders, but only poorly crosses the blood-brain barrier. We determined the sensitivity of the two human NKCC1 splice variants to bumetanide and various other chemically diverse loop diuretics, using the Xenopus oocyte heterologous expression system. Azosemide was the most potent NKCC1 inhibitor (IC50s 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B), being about 4-times more potent than bumetanide. Structurally, a carboxylic group as in bumetanide was not a prerequisite for potent NKCC1 inhibition, whereas loop diuretics without a sulfonamide group were less potent. None of the drugs tested were selective for hNKCC1B vs. hNKCC1A, indicating that loop diuretics are not a useful starting point to design NKCC1B-specifc compounds. Azosemide was found to exert an unexpectedly potent inhibitory efect and as a non-acidic compound, it is more likely to cross the blood-brain barrier than bumetanide. Te Na+–K+–2Cl− cotransporter NKCC1 (encoded by SLC12A2) plays an important role in Cl- uptake in neu- rons both in developing brain and in adult sensory neurons1,2.
    [Show full text]
  • Simultaneous Determination of 5 Diuretic Drugs Using an HPLC Method by Quantitative Analysis of Multiple Components by a Single Marker
    Simultaneous determination of 5 diuretic drugs using an HPLC method by quantitative analysis of multiple components by a single marker Fuchao Chen Hubei University of Medicine Baoxia Fang Hubei University of Medicine Peng Li ( [email protected] ) Hubei University of Medicine Sicen Wang Xi'an Jiaotong University Research Article Keywords: Diuretic drug, Multi-components detection with a single marker, HPLC, Method development Posted Date: April 8th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-397940/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Simultaneous determination of 5 diuretic drugs using an HPLC method by quantitative analysis of multiple components by a single marker Fuchao Chen 1, Baoxia Fang 1, Peng Li 1 *, and Sicen Wang 2 * 1 Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, 442008, P.R. China. 2 School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, Shanxi, PR China. Fu-chao Chen and Baoxia Fang contributed equally to this work and should be considered as equal first authors. Correspondence to: Peng Li, E- mail: [email protected]. Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, 442008, P.R. China.Sicen Wang, E- mail: [email protected]. School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, Shanxi, PR China. Abstract: Background: Loop diuretics are commonly used in clinical practice to manage high fluid loads and to control fluid balance. In this paper, a novel quantitative analysis method for multiple components with a single marker (QAMS) was developed for the simultaneous determination of 5 diuretic drugs furosemide, torasemide, azosemide, etacrynic acid, and bumetanide, by HPLC.
    [Show full text]
  • Tepzz 77889A T
    (19) TZZ T (11) EP 2 277 889 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.01.2011 Bulletin 2011/04 C07K 1/00 (2006.01) C12P 21/04 (2006.01) C12P 21/06 (2006.01) A01N 37/18 (2006.01) (2006.01) (2006.01) (21) Application number: 10075466.2 G01N 31/00 C07K 14/765 C12N 15/62 (2006.01) (22) Date of filing: 23.12.2002 (84) Designated Contracting States: • Novozymes Biopharma UK Limited AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nottingham NG7 1FD (GB) IE IT LI LU MC NL PT SE SI SK TR (72) Inventors: (30) Priority: 21.12.2001 US 341811 P • Ballance, David James 24.01.2002 US 350358 P Berwyn, PA 19312 (US) 28.01.2002 US 351360 P • Turner, Andrew John 26.02.2002 US 359370 P King of Prussia, PA 19406 (US) 28.02.2002 US 360000 P • Rosen, Craig A. 27.03.2002 US 367500 P Laytonsville, MD 20882 (US) 08.04.2002 US 370227 P • Haseltine, William A. 10.05.2002 US 378950 P Washington, DC 20007 (US) 24.05.2002 US 382617 P • Ruben, Steven M. 28.05.2002 US 383123 P Brookeville, MD 20833 (US) 05.06.2002 US 385708 P 10.07.2002 US 394625 P (74) Representative: Bassett, Richard Simon et al 24.07.2002 US 398008 P Potter Clarkson LLP 09.08.2002 US 402131 P Park View House 13.08.2002 US 402708 P 58 The Ropewalk 18.09.2002 US 411426 P Nottingham 18.09.2002 US 411355 P NG1 5DD (GB) 02.10.2002 US 414984 P 11.10.2002 US 417611 P Remarks: 23.10.2002 US 420246 P •ThecompletedocumentincludingReferenceTables 05.11.2002 US 423623 P and the Sequence Listing can be downloaded from the EPO website (62) Document number(s) of the earlier application(s) in •This application was filed on 21-09-2010 as a accordance with Art.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • SUPPLEMENTARY MATERIAL 1: Search Strategy
    SUPPLEMENTARY MATERIAL 1: Search Strategy Medline search strategy 1. exp basal ganglia hemorrhage/ or intracranial hemorrhages/ or cerebral hemorrhage/ or intracranial hemorrhage, hypertensive/ or cerebrovascular disorders/ 2. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or pon$ or lentiform$ or brainstem or cortic$ or cortex$ or subcortic$ or subcortex$) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw 3. ((hemorrhag$ or haemorrhag$) adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw 4. (ICH or ICHs or PICH or PICHs).tw 5. 1 or 2 or 3 or 4 6. exp blood pressure/ 7. exp hypertension/ 8. (blood pressure or bloodpressure).tw 9. ((bp or blood pressure) adj5 (lowering or reduc$)).tw 10. ((strict$ or target$ or tight$ or intens$ or below) adj3 (blood pressure or systolic or diastolic or bp or level$)).tw 11. (hypertension or hypertensive).tw 12. ((manage$ or monitor$) adj3 (hypertension or blood pressure)).tw 13. ((intense or intensive or aggressive or accelerated or profound or radical or severe) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 14. ((standard or normal or ordinary or guideline or guide line or guideline recommend$ or recommend$ or convention$ or usual or established) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 15. (antihypertensive adj2 (agent$ or drug$ or medicat$)).tw 1 16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 17.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Superiority of Long-Acting to Short-Acting Loop Diuretics in The
    Advance Publication by J-STAGE Circulation Journal LATE BREAKING CLINICAL TRIAL (JCS 2012) Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Superiority of Long-Acting to Short-Acting Loop Diuretics in the Treatment of Congestive Heart Failure – The J-MELODIC Study – Tohru Masuyama, MD; Takeshi Tsujino, MD; Hideki Origasa, PhD; Kazuhiro Yamamoto, MD; Takashi Akasaka, MD; Yutaka Hirano, MD; Nobuyuki Ohte, MD; Takashi Daimon, PhD; Satoshi Nakatani, MD; Hiroshi Ito, MD Background: Diuretics are the most prescribed drug in heart failure (HF) patients. However, clinical evidence about their long-term effects is lacking. The purpose of this study was to compare the therapeutic effects of furosemide and azosemide, a short- and long-acting loop diuretic, respectively, in patients with chronic heart failure (CHF). Methods and Results: In this multicenter, prospective, randomized, open, blinded endpoint trial, we compared the effects of azosemide and furosemide in patients with CHF and New York Heart Association class II or III symptoms. 320 patients (160 patients in each group, mean age 71 years) were followed up for a minimum of 2 years. The pri- mary endpoint was a composite of cardiovascular death or unplanned admission to hospital for congestive HF. During a median follow-up of 35.2 months, the primary endpoint occurred in 23 patients in the azosemide group and in 34 patients in the furosemide group (hazard ratio [HR], 0.55, 95% confidence interval [CI] 0.32–0.95: P=0.03). Among the secondary endpoints, unplanned admission to hospital for congestive HF or a need for modification of the treatment for HF were also reduced in the azosemide group compared with the furosemide group (HR, 0.60, 95%CI 0.36–0.99: P=0.048).
    [Show full text]
  • Role of Bumetanide on Insulin Secretion
    Wright State University CORE Scholar Browse all Theses and Dissertations Theses and Dissertations 2014 Role of Bumetanide on Insulin Secretion Mohammed Mashari Almutairi Wright State University Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all Part of the Pharmacology, Toxicology and Environmental Health Commons Repository Citation Almutairi, Mohammed Mashari, "Role of Bumetanide on Insulin Secretion" (2014). Browse all Theses and Dissertations. 2030. https://corescholar.libraries.wright.edu/etd_all/2030 This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE Scholar. For more information, please contact [email protected]. ! ! ! ! ! ! Role%of%Bumetanide%on%Insulin%Secretion% % ! ! ! A!thesis!submitted!in!partial!fulfillment! of!the!requirements!for!the!degree!of!! Master!of!Science! ! ! By! ! MOHAMMED!MASHARI!ALMUTAIRI! ! B.!Pharm,!King!Saud!University,!Riyadh,!Saudi!Arabia!2010! ! ! ! ! ! 2014! ! Wright!State!University! WRIGHT STATE UNIVERSITY GRADUATE SCHOOL Date: July 22, 2014 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY Mohammed M Almutairi ENTITLED “Role of Bumetanide on Insulin Secretion” BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science. Mauricio Di Fulvio, Ph.D. Thesis Director Norma Adragna, Ph.D. Interim Chair Department of Pharmacology and Toxicology Committee on Final Examination Mauricio Di Fulvio, Ph.D. Norma Adragna, Ph.D. David Cool, Ph.D. Robert E. W. Fyffe, Ph.D. Vice President for Research and Dean of the Graduate School ABSTRACT Almutairi, Mohammed. M.S., Department of Pharmacology and Toxicology, Wright State University, Boonshoft School of Medicine, 2014.
    [Show full text]
  • Decision Trees to Characterise the Roles of Permeability and Solubility on the Prediction of Oral Absorption
    Decision trees to characterise the roles of permeability and solubility on the prediction of oral absorption Article (Accepted Version) Newby, Danielle, Freitas, Alex A and Ghafourian, Taravat (2015) Decision trees to characterise the roles of permeability and solubility on the prediction of oral absorption. European Journal of Medicinal Chemistry, 90. pp. 751-765. ISSN 0223-5234 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/64123/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version. Copyright and reuse: Sussex Research Online is a digital repository of the research output of the University. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available. Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. http://sro.sussex.ac.uk Accepted Manuscript Decision trees to characterise the roles of permeability and solubility on the prediction of oral absorption Danielle Newby , Alex.
    [Show full text]